GREY:TBPMQ - Post by User
Comment by
SamV21on Oct 24, 2021 10:16pm
79 Views
Post# 34043301
RE:Why are we spending money on Reduvo again ? Please do tell.
RE:Why are we spending money on Reduvo again ? Please do tell.Nabilone is a prescription synthetic cannabinoid receptor agonist that is used in the treatment of chemotherapy-induced vomiting as well as off-label use for chronic pain. Nabilone is typically used to treat severe nausea and vomiting associated with certain types of cancer chemotherapy and can be used to stimulate appetite. Nabilone is also used to treat chronic nerve related pain.
Both dronabinol and nabilone are administered orally. Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC)-the psychoactive ingredient of cannabis. Nabilone is also a synthetic cannabinoid that is similar to THC but appears to be more potent.So why would the approve Reduvo if it is not as potent ?
This has been in Canada since 2006 , Teva makes it, has multiple Canadian DIN numbers for each dose and has made it for years. I have not heard of any head to head studies Reduvo verses Nabilone.He keeps saying first avaliable synthetic drug cannabinoid in Canada, is it ? Will this effect Tetras market share ? What is the truth here ? Has he done a cost to produce comparison with the competition? Maybe this is why the big pharma companies are just sitting back and not investing or interested at this point in Tetra.
I have also read that there is a drug shortage of Nabilone at present and provincial insurance plans are not granting coverage in all cases.Just because it is a prescription drug doesn't mean it is 100% covered, everyone knows how insurace companies don't like to pay money out for anything.Sounds like some of the compounds are the same, will Tetra or Gentelxol be able to produce quantity. Teva is a 10 Billion dollar company making Nabilone since 2006, things just don't add up here, would Tetras share of the market even make it profitable ? We were lead to believe Reduvo was going to make us all rich , I have read the average net profit on a drug is about 13% , not much if that is the case the 121 million over 5 years would only be 15,750,000 over 5 years , thats only 3,150,000 a year from Reduvo and they never mentioned competing with Nabilone from Teva for market share.